louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06558357: Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica
Official title: Evaluation of the Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica and Comparison With Others Inflammatory Rheumatic Diseases.
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Inflammatory Rheumatism
18-FDG
Positron-emission Tomography
Keywords: Polymyalgia rheumatica
FDG
PET
Diagnostic performance
score
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2024-08-16
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Maximum age (years): 110
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult with inflammatory rheumatism confirmed by specialist, with or without treatment and having a 18-FDG-PET CT.

Brief summary: Study of the diagnostic performance of 18-FDG PET scores in Polymyalgia rheumatica and comparaison with others inflammatories diseases.

Detailed description: Polymyalgia Rheumatica is difficult to diagnostic because symptoms are non specific and many diseases can be differential diagnosis (cancer, infections, others rheumatisms...).

PET-CT is more often used to help for diagnostic of inflammatory disease, and particularly inflammatory rheumatism.

Some scores have been described to harmonize the diagnosis of Polymyalgia rheumatica.

The aim of this study is to evaluate the diagnostic performance of 18-FDG PET scores in Polymyalgia rheumatica and compared with others inflammatories diseases such as ankylosing spondylarthritis.

This is a multicentric retrospective study.

Eligibility criteria: Inclusion Criteria:

* Having 18-FDG PET-CT between 2012 and 2024
* Diagnosis of inflammatory rheumatism by specialist doctor
* Adult without opposition to use there data for research
* Affiliate to social security system

Exclusion Criteria:

* Refusal participation
* Patient under juridic protection

Primary outcomes:
measure: Diagnostic performance of 18-FDG PET scores for diagnostic of Polymyalgia rheumatica.
timeFrame: up to 9 months
Secondary outcomes:
measure: Analysis of SUV and visual fixation of mains joints.
timeFrame: up to 9 months
measure: Diagnostic performance of 18-FDG PET scores for diagnostic of others inflammatory rheumatism.
timeFrame: up to 9 months
measure: Comparaison of scores with clinical, biological and radiological data.
timeFrame: up to 9 months
Other outcomes:
Locations:
city: Brest
country: France
facility: Chu Brest
Study officials:
affiliation: CHU Brest
name: Solène QUERELLOU
role: STUDY_DIRECTOR
References:
Clinical trial NCT03349957: TACE for HCC by TANDEM and Idarubicin
Official title: Retrospective Study on TACE for HCC by TANDEM and Idarubicin
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatocellular Carcinoma (HCC)
Keywords: TACE
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2017-11-22
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients treated by TACE for HCC by TANDEM and idarubicin

Brief summary: DcBeads and lipiodol-transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using doxorubicin result in about 50% objective response rate at 6 months (Precision V study, Lammer et al. CVIR 2010) We previously demonstrated that idarubicin was the most effective drug on 3 HCC cell lines (Boulin et al., Anticancer drugs 2009). We tested idarubicin-loaded beads in a phase I trial (Boulin et al., Aliment Pharmacol Therapy 2012) and more recently in a prospective multicentric phase II trial (IDASPHERE II, Magna Cum Laude CIRSE 2017, B Guiu et al.). This trial was stopped at interim analysis because the endpoint was reached.

Tandem beads are precisely calibrated, of small size, allowing the maximization of ischemic effects together with an optimal efficacy of the drug. We previously published that idarubicin was able to load fastly in Tandem, with minimal modification of bead diameter and a very interesting releasing profile of the drug (Guiu et al., JVIR 2015).

We used TANDEM combined with idarubicin in our practice for the treatment of HCC by TACE (in-label use of beads and the drug).

No clinical study (even retrospective) has been published so far with TANDEM-IDA (except our first paper published in JVIR in 2015, only 4 patients).

Here we propose to collect the retrospective data of patients treated by TANDEM-IDA, to help to design a future multicentric randomized phase II trial


Eligibility criteria: Inclusion Criteria:

HCC according to histological examination or Barcelona criteria Measurable targets according to mRECIST v1.1 Child A or B7 cirrhosis (without decompensation in the past 6 months) HCC not candidate to surgery or ablation Age ≥ 18 years Performance status 0 or 1 Thrombocytes ≥ 50 000/mm3, neutrophil count≥ 1 000/mm3, creatininemia ≤ 150 µmol/L No cardiac failure

Exclusion Criteria:

Follow-up \< 1month Lobar/main portal venous thrombus Prior treatment by systemic chemotherapy or radioembolization

Primary outcomes:
measure: tumeur response
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Boris GUIU, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04952857: Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease
Official title: Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Covid19
Lead sponsor: PGIMER
Sponsor class: UNKNOWN
First posted: 2021-07-07
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: COVID-19 caused by SARS-CoV-2 virus has affected the lives of millions of individuals globally and also severely strained the medical community. Pre-symptomatic and asymptomatic SARS-CoV-2 positive individuals far outnumber the symptomatic ones or those with severe disease. The transmission potential of SARS CoV-2 is potentially greater than earlier viral outbreaks of SARS-CoV and MERS-CoV.Routine measures of social distancing, personal hand hygiene and limited outdoor contact activities have shown benefits to limit corona virus infection. However, the role of vitamin D in SARS-CoV-2 infection is sparingly explored despite the knowledge of an immunomodulatory role and protective effect of vitamin D against viral infections. Meta-analysis of five clinical trials of vitamin D supplementation found that those receiving vitamin D supplementation had fewer respiratory tract infections (odds ratio = 0.58 (95%CI, 0.42 - 0.81).Any immune-modulatory effect of vitamin D is likely to be observed at levels which are considered higher than that required for normal bone metabolism.


Eligibility criteria: Inclusion Criteria:

1. RT-PCR proven SARS-CoV-2 infection or computed tomography scan findings compatible with the COVID19 disease (bilateral multifocal ground-glass opacities ≥50%)
2. Moderate to severe COVID-19 defined by PFR ratio of \<200
3. SOFA score\>4
4. Patients with vitamin D deficiency defined as 25 (OH)D level\<20 ng/ml
5. Age\>18 years

Exclusion Criteria:

* 1. Vitamin D sufficient or already receiving vitamin D supplements 2. Active malignancy 3. Hypercalcemia, hyperparathyroidism 4. Chronic kidney disease (eGFR\<30 ml/min) 5. Pregnant and lactating women 6. Patient on mechanical ventilation at ICU admission

Primary outcomes:
measure: Sequential Organ Failure Assessment (SOFA)
timeFrame: 7 days
Secondary outcomes:
measure: Sequential Organ Failure Assessment (SOFA) Score
timeFrame: 3 days
measure: Sequential Organ Failure Assessment (SOFA) score
timeFrame: 14 days
Other outcomes:
Locations:
city: Chandigarh
country: India
facility: Deptt of Endocrinology
Study officials:
References:
Clinical trial NCT02332057: Diclofenac Plus Lidocaine Gel for Pain Relief During Intrauterine Device Insertion(IUD).
Official title: Diclofenac Plus Lidocaine Gel for Pain Relief During Intrauterine Device (IUD) Insertion. A Randomized Double Blinded Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pain
Keywords: IUD,Diclofenac , Lidocaine
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2015-01-06
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine the effectiveness of a combination of diclofenac and lidocaine gel in reducing pain during IUD insertion.

Detailed description: Various studies evaluating the use of local anesthetics or misoprostol prior to IUD insertion have mixed results.We think that the combination of diclofenac and lidocaine gel could be more successful in relieving pain during IUD insertion than single therapy.The aim of this study is to determine the effectiveness of a combination of diclofenac and lidocaine gel in reducing pain during IUD insertion.

Eligibility criteria: Inclusion Criteria:

* Patients of reproductive age requesting IUD for contraception

Exclusion Criteria:

* Patients with contraindications to IUD insertion ( less than 6 weeks postpartum, less than 2 weeks after abortion, uterine anomalies, fibroid distorting uterine cavity, pregnancy, pelvic inflammatory disease, cervicitis, uterine depth less than 6 cm or more than 9 cm) , previous IUD insertion, allergy to diclofenac or lidocaine, peptic ulcer , asthma, bleeding disorders, cardiac, liver or kidney diseases.

Primary outcomes:
measure: Intensity of pain
timeFrame: Pain intensity will be assessed by visual analogue scale during the procedure [an expected average of 3 minutes]
Secondary outcomes:
measure: Adverse effects of diclofenac and lidocaine
timeFrame: Within 24 hours after IUD insertion
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Obstetrics and Gynecology Department,Cairo university
Study officials:
affiliation: Cairo University
name: Usama M Fouda, M.D,PhD
role: STUDY_CHAIR
References:
citation: McNicholas CP, Madden T, Zhao Q, Secura G, Allsworth JE, Peipert JF. Cervical lidocaine for IUD insertional pain: a randomized controlled trial. Am J Obstet Gynecol. 2012 Nov;207(5):384.e1-6. doi: 10.1016/j.ajog.2012.09.018. Epub 2012 Sep 20.
citation: Fouda UM, Salah Eldin NM, Elsetohy KA, Tolba HA, Shaban MM, Sobh SM. Diclofenac plus lidocaine gel for pain relief during intrauterine device insertion. A randomized, double-blinded, placebo-controlled study. Contraception. 2016 Jun;93(6):513-8. doi: 10.1016/j.contraception.2016.02.001. Epub 2016 Feb 4.
Clinical trial NCT06035757: The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
Official title: The Effect of Administration of Sugammadex on the Occurrence of Emergence Agitation in Pediatric Strabismus Surgery-prospective Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Emergence Delirium
Strabismus
Pediatric ALL
Lead sponsor: Konkuk University Medical Center
Sponsor class: OTHER
First posted: 2023-09-13
Enrollment: 76
Sex: ALL
Minimum age (years): 4
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The present trial conducted to demonstrate the administration of sugammadex as reversal of neuromuscular blockade agent reduces the incidence of emergence agitation (EA) comparing to neostigmine

Detailed description: EA is one of the most common postoperative complications in after general anesthesia in pre-school aged pediatric patients. There are several causes contributed to occurrence of EA such as postoperative pain, type of surgery and surgical site, hyperthermia or hypothermia. Some researches showed that the occurrence of EA is associated with patients' anxiety and investigators of this trial inferred that patients' anxiety after general anesthesia could be related to ability to breathe. Ability to breathe is highly associated with level of residual neuromuscular blockade (NMB) after recovery from general anesthesia. Investigators evaluate the Pediatric Anesthesia Emergence Delirium (PAED) Scale to investigate whether sugammadex as reversal agents of NMB reduces the incidence of EA in pediatric patients who undergo strabismus surgery.

Eligibility criteria: Inclusion Criteria:

* Patients scheduled elective strabismus surgery aged 4-7 with American Society of Anesthesiologists (ASA) classification 1-3.

Exclusion Criteria:

* ASA classification 3 or more
* impaired liver function
* impaired kidney function
* myasthenia gravis or other neuromuscular disorders
* history of drug allergy
* cardiovascular disease or arrhythmia

Primary outcomes:
measure: The incidence of EA in postanesthesia care unit (PACU)
timeFrame: EA is assessed three times at 15-minute intervals in PACU until discharge from PACU.
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Konkuk University Medical Center
state: Seoul-T'ǔkpyǒlshi
Study officials:
affiliation: Konkuk University Medical Center
name: Yea-Ji Lee, M.D Ph. D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00556257: Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients
Official title: A Pilot Randomized, Multicenter, Open-Label, Active Comparator-Controlled Trial Of A CP-690,550-Based Regimen In De Novo Kidney Allograft Recipients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Kidney Transplantation
Keywords: Immunosuppression, JAK3 inhibitor, kidney transplantation
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2007-11-09
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.


Eligibility criteria: Inclusion Criteria:

* Recipient of first time kidney transplant
* Between the ages of 18 and 70 years, inclusive

Exclusion Criteria:

* Recipient of any non-kidney transplant

Primary outcomes:
measure: Clinical biopsy proven acute rejection rate at 6 months
timeFrame: 6 months
Secondary outcomes:
measure: Pharmacokinetics of CP-690,550
timeFrame: 12 months
measure: Lymphocyte subsets
timeFrame: 12 months
measure: Posttransplant humoral alloreactivity
timeFrame: 12 months
measure: Safety and tolerability of CP-690,550
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT01069757: A Study of ARQ 197 in Combination With Erlotinib
Official title: A Phase I Study of ARQ 197 in Combination With Erlotinib in Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Non-small-cell Lung Cancer
Keywords: Advanced/recurrent non-small-cell lung cancer
Lead sponsor: Kyowa Kirin Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2010-02-17
Enrollment: 16
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase I study to determine the safety, tolerability and recommended phase II dose of ARQ 197 given in combination with erlotinib as primary endpoints in patients with advanced/recurrent non-small-cell lung cancer. The pharmacokinetic profile and antitumor activity of ARQ 197 administered alone or in combination with erlotinib will also be determined as secondary endpoints.


Eligibility criteria: Inclusion Criteria:

* Voluntary written informed consent for study participation must be obtained
* A histologically or cytologically confirmed advanced/recurrent non-small-cell lung cancer
* History of ≥1 prior chemotherapy regimen (treatment with EGFR tyrosine kinase inhibitors will be counted as one regimen)
* ECOG PS of 0 or 1
* Life expectancy of ≥3 months

Exclusion Criteria:

* Anti-cancer chemotherapy, anti-cancer therapy with EGFR-TKI, hormone therapy, radiotherapy, immunotherapy, other investigational agents or anti-cancer antibody therapy within 28 days prior to ARQ 197 dose
* Surgery for cancer within 28 days prior to ARQ 197 dose
* Active double cancer
* Known symptomatic brain metastases
* An intercurrent illness that is uncontrolled (e.g., infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic arrhythmia, interstitial pneumonia)
* Pregnant or lactating
* Subjects who wish to have a child and who would not agree to use contraceptive measures

Primary outcomes:
measure: Dose-Limiting Toxicity in the combination of tivantinib and erlotinib
timeFrame: DLT observation period started from the day of first single agent treatment to the day after the continuous combination treatment for 29 days.
Secondary outcomes:
measure: Plasma concentration and pharmacokinetic parameters of ARQ 197 and Erlotinib
timeFrame: Plasma sample correction at pre-dose, 1, 2, 4, 6, 10, 12 and 24 hours on Day 1; at pre-dose, 1, 2, 4, 6, 10, 12 hours on the day of the first comnibation treatment
measure: Antitumor activity
timeFrame: Baseline, and then every 6 week of imaging until discontinuation criteria met
Other outcomes:
Locations:
city: Osaka
country: Japan
city: Shizuoka
country: Japan
Study officials:
References:
Clinical trial NCT00699257: A Clinical Investigation of the Oxford® Partial Knee System
Official title: A Prospective, Non-controlled, Clinical Investigation of the Oxford® Partial Knee System
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Osteoarthritis
Keywords: Partial Knee Arthroplasty
Partial Knee Replacement
Arthritis of Medial Compartment of the Knee
Oxford Knee
Lead sponsor: Zimmer Biomet
Sponsor class: INDUSTRY
First posted: 2008-06-17
Enrollment: 85
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients that have already made the decision to undergo knee surgery and will receive the Oxford® Partial Knee System.

Brief summary: The purpose of this prospective data collection is to document the performance and clinical outcomes of the Oxford® Partial Knee System.


Eligibility criteria: Inclusion Criteria:

* For use in individuals with osteoarthritis or avascular necrosis limited to the medial compartment of the knee. The implant is intended to be implanted with bone cement.

Exclusion Criteria:

* Infection
* Use in the lateral compartment of the knee
* Rheumatoid arthritis or other forms of inflammatory joint disease
* Revision of a failed prosthesis, failed upper tibial osteotomy or post-traumatic arthritis after tibial plateau fracture
* Insufficiency of the collateral, anterior, or posterior cruciate ligaments which would preclude stability of the device
* Disease or damage to the lateral compartment of the knee
* Uncooperative patient or patient with neurologic disorders who is incapable of following directions
* Osteoporosis
* Metabolic disorders which may impair bone formation
* Osteomalacia
* Distant foci of infections which may spread to the implant site
* Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram
* Vascular insufficiency, muscular atrophy, neuromuscular disease
* Incomplete or deficient soft tissue surrounding the knee
* Charcot's disease
* A fixed varus deformity (not passively correctable) of greater than 15 degrees
* A flexion deformity greater than 15 degrees

Primary outcomes:
measure: Knee Society Score
timeFrame: 6 weeks, 3 months, 1 year, 3 years, 5 years
measure: Oxford-12 Self Assessment Form
timeFrame: 6 weeks, 3 months, 1 year, 3 years, 5 years
Secondary outcomes:
measure: Incidence of revisions and removals
timeFrame: Any time
Other outcomes:
Locations:
Study officials:
affiliation: Clinical Research, Biomet Orthopedics, LLC
name: Kenneth J Beres, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02628457: Did MRI Appearance of Supraspinatus Muscle Atrophy Changes After Repair of All Kind of Rotator Cuff Tear?
Official title: Did MRI Appearance of Supraspinatus Muscle Atrophy Changes After Repair of All Kind of Rotator Cuff Tear?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Rotator Cuff Tear
Keywords: occupation ratio
pseudoatrophy
Lead sponsor: CM Chungmu Hospital
Sponsor class: OTHER
First posted: 2015-12-11
Enrollment: 209
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 209 patients with degenerative rotator cuff tear who underwent single-row arthroscopic rotator cuff repair between March 2012 and April 2015 in CM hospital

Brief summary: There are two purpose of this study, first is to find whether arthroscopic rotator cuff repair is changing the appearance of supraspinatus muscle atrophy in each and every patient. Second, is to find how much approximate change one can expect depending on age and tendon retraction

Detailed description: Retrospective review of 209 patients having both preoperative and immediate postoperative MRI done. Both preoperative and immediate postoperative occupancy ratio calculated and from that change in occupancy ratio calculated for each and every patient. Patient were divided in two major group according to age that is \<60 years and \>60 years and 3 subgroups of mild, moderate and severe depending on preoperative supraspinatus tendon retraction on coronal view of MRI. Postoperative occupation ratio was compared with preoperative occupation ratio within the subgroups and change in occupation ratio was used for comparison between the subgroup. Change in occupation ratio was also used for comparison between 2 major groups

Eligibility criteria: Inclusion Criteria:

1. Patients with degenerative rotator cuff tear who underwent single-row arthroscopic rotator cuff repair in our hospital.
2. Patients with preoperative MRI and postoperative MRI within 1 week of surgery in our hospital.
3. Patients with minimum grade 1 supraspinatus atrophy in preoperative MRI.

Exclusion Criteria:

1. Patients with preoperative MRI from outside hospital.
2. Patients with isolated subscapularis tear.
3. Patients with previous operation on the same shoulder joint.
4. Patients with MRI images that were not usable due to poor quality or absence of appropriate Y-view.

Primary outcomes:
measure: change in supraspinatus muscle atrophy
timeFrame: within 1 week after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Yeongdeungpo-gu
country: Korea, Republic of
facility: Chungmu General Hopsital
state: Seoul
Study officials:
affiliation: President, CM general Hospital
name: sang-Hoon Lhee, MD PhD
role: STUDY_CHAIR
affiliation: arthroscopy fellow, CM general Hospital
name: Anant kumar Singh
role: PRINCIPAL_INVESTIGATOR
References: